Integra LifeSciences Q3 Revenue $410M-$412M; Cuts FY26 Guidance

Integra LifeSciences Holdings Corporation announced preliminary unaudited results for the third quarter of 2026, which were impacted by flooding at its Cincinnati facility. The company expects Q3 revenue between $410 million and $412 million, with an estimated $7 million impact from supply disruptions. Adjusted earnings per diluted share are projected to be between $0.55 and $0.59, and operating cash flow is expected to exceed $85 million. The company has updated its full-year 2026 guidance, lowering revenue expectations to $1.634 billion - $1.654 billion and adjusted EPS to $2.30 - $2.40, while maintaining strong operating cash flow projections of $190 million - $200 million. Full manufacturing operations at the Cincinnati facility are anticipated by the second quarter of 2027.